What is Hyperimmune Globulins Market?
Hyperimmune globulins are high in antibodies that protect against specific diseases by providing passive immunity, an immunity achieved by administration of purified antibodies that provide immediate, but short-term, protection against the disease. Hyperimmune globulins are prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Recent studies estimate that hyperimmune globulins purified from plasma taken from people who have recovered from COVID-19 enhances the immune response to the virus and block its entry into cells. The factors such as Increased Prevalence of Autoimmune Disease and Increased Number of Cancer Patients are driving the global hyperimmune globulins market. Short Term Protection Against Disease and Stringent Government Rules and Regulations may hamper market growth.
The market study is being classified by Type (Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Tetanus Immunoglobulins and Others), by Application (Government Institutions, Private Sector and Others) and major geographies with country level break-up.
CSL Behring (United States), Grifols, S.A. (Spain), Biotest (Germany), Kedrion S.p.A. (Italy), Cangene (Canada), Kamada Ltd (Israel), China National Biotec Group Company (China), Hualan Biological Engineering Inc. (China), Shanghai RAAS blood products Co., Ltd. (China) and Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are ADMA Biologics (United States).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Hyperimmune Globulins market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Hyperimmune Globulins market by Type, Application and Region.
On the basis of geography, the market of Hyperimmune Globulins has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- High Demand for Covid-19 Infected Patients to Enhance Immune Response
- Increased Prevalence of Autoimmune Disease
- Increased Number of Cancer Patients
- Increased Number of Hospitals and Clinics
- High Research and Development Investments
- Short Term Protection Against Disease
- Availability of Alternative Treatments
- Growing Geriatric Population Worldwide
- Increasing Health Awareness among People
- Current Covid-19 Panedemic around the World
- Stringent Government Rules and Regulations
In April 2020, Kamada Ltd. and Kedrion Biopharma, two prominent biopharmaceutical companies specialized in plasma-derived protein therapeutics,has announced a global collaboration for the development, manufacturing and distribution of a human plasma-derived Anti-SARs-COV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for coronavirus patients.
Key Target AudienceHyperimmune Globulins Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase